news & meetings - latest announcements & happenings | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Nonprofit CureDuchenne Is Encouraged To See Gene Editing For Duchenne Advance Through Vertex’s Acquisition Of Exonics Therapeutics
Business

Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exonics Therapeutics

CureDuchenne, a nonprofit global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), is enthusiastic with today’s announcement that Exonics Therapeutics, a research company focused on CRISPR/Cas-9 technologies to treat Duchenne muscular dystrophy, has been acquired by Vertex. The acquisition by Vertex, a successful and well-respected biotech company, validates CureDuchenne’s venture philanthropy business model of funding early stage science to advance promising Duchenne research projects.

Jun 6, 2019
PTC Therapeutics Announces First-Ever Winners Of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
Business

PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

PTC Therapeutics, Inc. today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year's funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.

"We were overwhelmed to receive so many outstanding applications in the first year of PRIORITY and to see such a breadth of ideas to improve the screening and diagnosis of Duchenne," said Dr. Claudio Santos, Senior Vice President, Global Medical Affairs, PTC Therapeutics, Inc. "We are thrilled that the PRIORITY program will help bring these research projects to fruition and ultimately help patients receive the best care as early as possible."

May 20, 2019